Uncovering Inversion Formation in the Human Genome and its Impact to Disease

The relevance of inversions for disease causation, speciation and adaptation is broadly recognized, although the prevalence of inversions is unknown. In humans, de novo inversions are associated with congenital anomalies in approximately 9.6% of patients. Yet, despite the biological relevance of inversions, their molecular features, formation mechanism, impact to the genomic structure of carriers, as well as their contribution to clinical phenotypes, have not been further explored. Inversions are typically classified as balanced reciprocal events generated by ectopic recombination, although recent studies reveal a distinct picture whereby inversions originate from mechanisms that concomitantly generate copy number variants (CNVs). Surprisingly, those complex inversions underlie as much as 30% of neurodevelopmental-associated CNVs.

The hypothesis of this project are:

1. inversions are often generated de novo by mechanisms other than ectopic recombination
2. a relevant fraction of inversions are associated with complex genomic rearrangements (CGRs), often overlooked in sporadic diseases, and
3. inversions are a "hidden" type of structural variation for which contribution to a clinical phenotypes has been under assessed due to the lack of appropriate detection tools.

A combined strategy using multiple genomic tools will be applied to characterize inversions and associated genomic alterations in individuals with neurodevelopmental disorders and controls: whole genome sequencing (WGS) with short-and long-reads; genome mapping; classical cytogenetics; and array CGH. This project will establish common ground to bridge studies of rare and common diseases, human evolution, and population genetics.

• Study Design:
  • Case Set
• Study Type:
  • Case Set
  • Clinical Genetic Testing
  • Whole Genome Sequencing
• Total number of consented subjects: 93
• Subject Sample Telemetry Report (SSTR)

• Primary Phenotype: Genetic Diseases, Inborn
• Genetic Diseases, X-Linked

• MECP2

• Principal Investigator
  • Claudia Carvalho. Pacific Northwest Research Institute, Seattle, WA, USA.
• Co-Investigator
  • Fritz Sedlazeck. Baylor College of Medicine, Houston, TX, USA.
• Sequencing Center
  • Human Genome Sequencing Center. Baylor College of Medicine, Houston, TX, USA.